| Species |
Mouse |
| Protein Construction |
IL-31 RA (Val19-Thr499)_x000D_
Accession # Q8K5B1-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
56.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 80-115 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin-31 receptor A (IL-31RA) is a newly identified type I cytokine receptor, that is related to gp130, the common receptor of the interleukin (IL) -6 family cytokines. IL-31RA forms a functional receptor complex for IL-31 together with the beta subunit of oncostatin M receptor (OSMRbeta). OSMRbeta is expressed in a subset of small-sized nociceptive neurons of adult dorsal root ganglia (DRGs).IL-31 and OSM may thus have redundant functions in the development of OSMRbeta-expressing neurons. |
| Synonyms |
IL-31RA; IL-31R-alpha; Gp130-like receptor; CRL3; GPL; ZcytoR17; GLM-R; CRL3Glmr; GLM-RMGC125346; PRO21384 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
